Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

The failure of many new, mostly biologic, drugs to meet their primary end points in double-
blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a …

With the approval by the FDA in 2011 of a biologic agent (namely belimumab) for the
treatment of systemic lupus erythematosus (SLE), optimism abounds that additional biologic …

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting multiple organ systems that runs an unpredictable course and may present with a …

Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …

Systemic lupus erythematosus (SLE) has a complex clinical picture, and a number of defects
in the immune system have been described in patients with the disease. Most organs can be …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with substantial
clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and …

Objective This extension study of the Phase III, randomized, placebo-controlled Belimumab
International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder involving multiple
organs and having diverse clinical manifestations. Among the rheumatic diseases, it has …

Objective To investigate the long‐term safety and efficacy of intravenous (IV) belimumab
plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with …